Cited in:


This article has been cited by:

  1. 1
    G. V. Papatheodoridis, S. Manolakopoulos, G. Touloumi, G. Nikolopoulou, M. Raptopoulou-Gigi, C. Gogos, I. Vafiadis-Zouboulis, D. Karamanolis, A. Chouta, A. Ilias, C. Drakoulis, K. Mimidis, I. Ketikoglou, E. Manesis, M. Mela, G. Hatzis, G. N. Dalekos, Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort, Journal of Viral Hepatitis, 2015, 22, 2
  2. 2
    G. Papatheodoridis, C. Triantos, E. Hadziyannis, K. Zisimopoulos, A. Georgiou, T. Voulgaris, I. Vlachogiannakos, V. Nikolopoulou, S. Manolakopoulos, Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate, Journal of Viral Hepatitis, 2015, 22, 12
  3. 3
    Vahid Bagheri, Azam Askari, Mohammad Kazemi Arababadi, Derek Kennedy, Can Toll-Like Receptor (TLR) 2 be considered as a new target for immunotherapy against hepatitis B infection?, Human Immunology, 2014, 75, 6, 549


  4. 4
    Ziba Shabani, Masomeh Bagheri, Mohammad Zare-Bidaki, Gholamhossein Hassanshahi, Mohammad Kazemi Arababadi, Mozafar Mohammadi Nejad, Derek Kennedy, NK cells in hepatitis B virus infection: a potent target for immunotherapy, Archives of Virology, 2014, 159, 7, 1555


  5. You have free access to this content5
    C. Pipili, E. Cholongitas, G. Papatheodoridis, Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease, Alimentary Pharmacology & Therapeutics, 2014, 39, 1